
Treatment better than placebo
time in weeks: mean HAQ CFB (95%CrI)
Adalimumab + MTX vs Placebo + MTX
24: -0.33 (-0.49; -0.17)
52: -0.34 (-0.45; -0.23)
Certolizumab pegol + MTX vs Placebo + MTX
24: -0.38 (-0.53; -0.24)
52: -0.42 (-0.52; -0.32)
Etanercept + MTX vs Placebo + MTX
24: -0.28 (-0.47; -0.09)
52: -0.34 (-0.60; -0.08)
Golimumab + MTX vs Placebo + MTX
24: -0.34 (-0.57; -0.11)
Infliximab + MTX vs Placebo + MTX
24: -0.19 (-0.31; -0.07)
52: -0.21 (-0.40; -0.02)
Rituximab + MTX vs Placebo + MTX
24: -0.21 (-0.40; -0.02)
52: -0.30 (-0.63; 0.04)
Tocilizumab + MTX vs Placebo + MTX
24: -0.21 (-0.44; 0.03)
Abatacept + MTX vs Placebo + MTX
24: -0.30 (-0.41; -0.18)
52: -0.29 (-0.38; -0.21)
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4